Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-inferiority of Zistdaru Danesh filgrastim vs Neupogen in prevention of neutropenic complications in breast cancer
IRCT20211218053442N1Phase 3Completed
- Sponsor
- Zistdaru Danesh
- Start
- Feb 2022
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of filgrastim in neutropenia and breast cancer (2 arms), sponsored by Zistdaru Danesh. Primary endpoint: Prevention of neutropenic complications. Started Feb 2022; status: completed.
02
Drugs
filgrastim
03
Conditions
neutropeniabreast cancer
Beyond the preview
Go deeper on IRCT20211218053442N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211218053442N1.